Navigation Links
Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection

py."

About Anadys

Anadys Pharmaceuticals, Inc., http://www.anadyspharma.com, is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company's programs focus on Toll-Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the believed favorable antiviral, metabolic, pharmacokinetic, and preliminary toxicologic properties of ANA598, the expected timing and plans for filing an IND and the possibility that ANA598 may play an important role in future HCV therapy. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. In particular, the results of in vitro studies and initial in vivo studies may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by other factors. In particular, there is no guarantee that Anadys and Novartis will be able to agree on future development activities for ANA975, that the FDA will lift the clinical hold on th
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 /PRNewswire/ ... the appointments of Dr. Ashraf Hanna , M.D., ... to its Board of Directors. Dr. Hanna is the ... Genentech and Chief Financial Officer for the Genentech Foundation, ... and Global Head of Business Development and Licensing for ...
(Date:9/18/2014)... Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage ... pain, announced today that it has appointed Mr. ... Director of Clinical Development. During his extensive ... led successful global clinical operations teams, in the US ... clinical development of numerous therapeutics and diagnostics across a ...
(Date:9/18/2014)... /CNW/ - A new expert panel report, Improving Medicines ... released today by the Council of Canadian Academies, addresses ... children. Each year about half of Canada,s ... prescription drug. Much of this prescribing is done off-label ... potential health risks. Children have historically been ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... publication in prominent peer-reviewed journal highlights,findings of ... infection, EVANSTON, Ill., March 17 ... using a,rapid molecular diagnostic test is effective ... published in the Annals of Internal Medicine,by ...
... on Track to Initiate Phase 2b in Second Quarter ... - Conference Call Tomorrow at 8:00 a.m. ... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced positive ... RDEA806, its novel,investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in,patients ...
Cached Medicine Technology:Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 2Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4
(Date:9/18/2014)... By Randy Dotinga ... -- Women who have the largest number of post-traumatic stress ... an addiction to food, a new study suggests. ... women overeating or becoming addicted to food. And it,s also ... experiencing trauma, PTSD, or both. Still, the research ...
(Date:9/18/2014)... 18, 2014 How much is a ... of the factors contributing to the obesity epidemic in ... single serving and how to manage portion size during ... Oct. 3 at Humility House, 755 Ohltown Road, Austintown. ... lead the informational discussion and answer questions from 12:30 ...
(Date:9/18/2014)... Texas Physical Therapy Specialists (TexPTS) is proud to ... Association (HPA) Friends and Family Golf tournament on ... tournament, which will take place at TopGolf from 9 ... through three golf challenges, “Top Scramble”, “Top Score”, and ... provided at the event and there will be open ...
(Date:9/18/2014)... Eye doctors have long known that staring ... basal tear film in the eyes to lose water and ... that staring at a computer screen can also alter the ... about computers, the tear film and dry eye for years ... (*Gray, Sarah, “Staring at Screen is Altering Your Tears, Study ...
(Date:9/18/2014)... 18, 2014 Members of United ... participating network dentists at UnitedConcordia.com, thanks to a ... company. , "Members can book an appointment with ... button located on the Find a Dentist page ... of network operations at United Concordia. "We are ...
Breaking Medicine News(10 mins):Health News:PTSD Link to Food Addiction Seen in Report 2Health News:PTSD Link to Food Addiction Seen in Report 3Health News:HMHP Workshop Addresses Portion Control 2Health News:Texas Physical Therapy Specialists Sponsoring HPA Friends & Family Golf Tournament 2Health News:New Study Confirms that Staring at a Computer Screen Alters Tear Film Content and Causes Dry Eye 2Health News:New Study Confirms that Staring at a Computer Screen Alters Tear Film Content and Causes Dry Eye 3Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 3
... , , LEXINGTON, Ky., Sept. ... stopping in Kentucky throughout the week of September 8 - 11 ... access information on programs that provide prescription medicines for free or ... -- one of the worst rates in the nation -- the ...
... BATESVILLE, Ind., Sept. 4 Hill-Rom Holdings, Inc. (NYSE: ... $0.1025 per share. This dividend was declared by Hill-Rom,s Board of ... to shareholders of record as of September 16, 2009. , , ... is a leading worldwide manufacturer and provider of medical technologies and related ...
... , , , DETROIT, Sept. ... Daniel J. Loepp made the following statement in conjunction with the ... with a serious illness. , , Blue Cross ... to jointly announce Mr. Harwell,s retirement as Blue Cross,s health and ...
... , , , ... Dk hybrid contact lens manufacturer, recently introduced a new ... revolutionary contact lens that takes advantage of the best ... centration, stability, and all-day comfort. The patent-pending design is ...
... , NEW HAVEN, Conn., Sept. 4 ... development and commercialization of novel antibiotics for the treatment of ... has joined the company as Chief Business Officer. In his ... activities. , , Mr. Kassberg, age 49, ...
... , NEW YORK, Sept. 4 Delcath Systems, ... its proprietary treatment method for primary and metastatic cancers to the ... make a presentation to investors at the Rodman & Renshaw 11th ... Time in New York. Mr. Hobbs will review the Company,s business ...
Cached Medicine News:Health News:Partnership for Prescription Assistance Prepared to Help Kentucky Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Kentucky Workers Hurt by Recession 3Health News:SynergEyes, Inc. Expands Launch of New Hybrid Contact Lens Design for Keratoconus Patients 2Health News:Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer 2
... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
... precise control of the thigh during varus/valgus manipulation ... the proximal thigh during ACL or PCL procedures. ... on both right and left legs and may ... Holder can be used with an Arthrex tourniquet ...
... for trauma, foot and ankle or deformity ... External Fixation components are designed to reduce ... the complexity of intra-operative and post-operative frame ... and hinges eliminate the need to stock ...
Medicine Products: